BBLG

Bone Biologics

BBLG

Market cap $3.81M

Overview Fund Activity

2.12 USD

+0.01

0.47%

At close Updated Sep 18, 11:16 AM EDT

1 day

0.47%

5 days

-1.4%

1 month

1.92%

3 months

-60%

6 months

-58.35%

Year to date

-64.01%

1 year

-83.01%

5 years

-99.97%

10 years

-99.97%

About: Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Employees: 2

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 [Q1] → 4 (+1) [Q2]

0.05% less ownership

Funds ownership: 0.13% [Q1] → 0.08% (-0.05%) [Q2]

91% less capital invested

Capital invested by funds: $20.8K [Q1] → $1.83K (-$19K) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

See Fund Rankings

Financial journalist opinion

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated com.

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and in.

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

Bone Biologics Announces Closing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares o.

Bone Biologics Announces Closing of $5.0 Million Public Offering

Why Is Bone Biologics Stock Surging On Friday?

Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.

Why Is Bone Biologics Stock Surging On Friday?

Bone Biologics Announces Pricing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a.

Bone Biologics Announces Pricing of $5.0 Million Public Offering

Bone Biologics Files Patent Application for Bone Regeneration Technology

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.

Bone Biologics Files Patent Application for Bone Regeneration Technology

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. Bone Biologics is now in compl.

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Announces 1-for-6 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “BBLG,”.

Bone Biologics Announces 1-for-6 Reverse Stock Split

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief ex.

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern tim.

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

See News Rankings

Charts implemented using Lightweight Charts™